Calcimimetic increases osteoprotegerin and decreases fetuin-A levels in dialysis patients

Messa, Piergiorgio; Alberti, Loredana; Como, Giovanna; Cerutti, Roberta; Mandujano, Bianca; Tirelli, Silvia; Torresani, Erminio; Brezzi, Brigida

doi:10.1093/ndt/gfm312

Cited by 18 publications

(15 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sir, In his letter to the editor [1] on our recent paper [2], Dr Cohen pointed out very important issues in the evaluation of the beneficial effects of cinacalcet, as yet unsolved in our study. We are currently unable to provide answers to these issues, due to the fact that cinacalcet has not yet been introduced to the Japanese market.…”

Section: Replymentioning

confidence: 97%

“…Cinacalcet: benefit and cost Sir, Fukagawa et al have confirmed the efficacy of cinacalcet in reducing the serum concentrations of parathyroid hormone (PTH) in long-term dialysis patients [1]. Their paper leaves some questions unanswered.…”

Section: Advanced Access Publication 8 December 2007mentioning

confidence: 99%

“…Sir, We read with interest the article by Messa et al, demonstrating that cinacalcet increases osteoprotegerin (OPG) and decreases fetuin-A serum levels, with no changes of interleukin-6 (IL-6) values [1].…”

Section: Replymentioning

confidence: 99%

See 2 more Smart Citations

Cinacalcet, fetuin-A and interleukin-6

Marino

Giotta

2007

Nephrology Dialysis Transplantation

View full text Add to dashboard Cite

Section: Replymentioning

confidence: 97%

Section: Advanced Access Publication 8 December 2007mentioning

confidence: 99%

See 1 more Smart Citation

Cinacalcet, fetuin-A and interleukin-6

Marino

Giotta

2007

Nephrology Dialysis Transplantation

View full text Add to dashboard Cite

“…In a recent uncontrolled clinical trial in hemodialysis patients, cinacalcet treatment was associated with an increase in serum osteoprotegerin and a decrease in serum fetuin-A levels (96). Because in CKD, both fetuin-A and osteoprotegerin play an important role in the pathogenesis of vascular calcification, the changes induced by cinacalcet could be interpreted as conferring an increased risk of vascular calcification.…”

Section: Adverse Effects Of Vitamin D Derivatives and Cinacalcetmentioning

confidence: 99%

Treatment of Secondary Hyperparathyroidism in CKD Patients with Cinacalcet and/or Vitamin D Derivatives

Drüeke¹,

Ritz²

2009

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

The discovery of the calcium-sensing receptor (CaR) 15 yr ago was rapidly followed by the development of drugs modulating its activity, the so-called calcimimetics (increasing the CaR signal) and calcilytics (decreasing the CaR signal). The indication for calcimimetics is treatment of primary and secondary hyperparathyroidism, whereas calcilytics have potential for treatment of osteoporosis. A large number of clinical studies has shown that cinacalcet, the only presently available calcimimetic, effectively reduces serum parathyroid hormone in dialysis patients with secondary hyperparathyroidism. In contrast to the effect of active vitamin D derivatives, it simultaneously decreases serum calcium and phosphorus. Experimental studies showed a concomitant decrease in parathyroid hyperplasia. In the treatment of secondary hyperparathyroidism of dialysis patients, important questions remain unresolved, for example, whether there are reasons to prefer calcimimetics to active vitamin D derivatives and whether combined administration offers advantages compared with calcimimetics or active vitamin D given in isolation. For lowering parathyroid hormone, available evidence from recent studies suggests that combination therapy should be preferred to single drug treatment because of less side-effects and greater efficacy in controlling parathyroid overfunction. Future randomized controlled trial must answer whether calcimimetics impact on cardiovascular events or survival and whether in this respect there are differences between vitamin D sterols and calcimimetics.

show abstract

“…Since it decreases the serum calcium levels as well as the requirement of active vitamin D, so the incidences of vascular calcification would be less with cinacalcet [18,19]. This effect may be mediated through altered mechanism of osteoprotegerin and fetuin-A following cinacalcet administration as shown by Messa et al [20]. These factors have been closely related to the occurrence of SHPT and vascular calcification in CKD.…”

Section: Discussionmentioning

confidence: 99%

Intermittent Dosing of Cinacalcet is also Effective in Treating Secondary Hyperparathyroidism in Hemodialysis Patients

Al-Hwiesh¹

2013

Pharmaceut Anal Acta 2013

View full text Add to dashboard Cite

show abstract

Calcimimetic increases osteoprotegerin and decreases fetuin-A levels in dialysis patients

Abstract: Longterm therapy with recombinant human erythropoietin decreases percentage of CD 152 þ lymphocytes in primary glomerulonephritis haemodialysis patients.

Cited by 18 publications

References 6 publications

Cinacalcet, fetuin-A and interleukin-6

Cinacalcet, fetuin-A and interleukin-6

Treatment of Secondary Hyperparathyroidism in CKD Patients with Cinacalcet and/or Vitamin D Derivatives

Intermittent Dosing of Cinacalcet is also Effective in Treating Secondary Hyperparathyroidism in Hemodialysis Patients

Contact Info

Product

Resources

About